10-Q: Quarterly report
10-K/A: Annual report (Amendment)
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, tod
No Data